Incyte (INCY) Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Incyte (INCY)

INCY 93.48

+1.0%

Oct 31 9:30 AM EDT

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: scaram(o)uche who wrote (3131)	6/8/2017 12:13:29 PM
From: tuck	Read Replies (2) of 3202

Probably need luck. Bought a second and last slug at $7.10 (so cost =$7.25), and would bail over $7.50. Feuerstein is calling indoximod an IDO inhibitor that's not an IDO inhibitor, as if it doesn't hit the target. I haven't seen any evidence to support that, though it doesn't mean there isn't any. If he's merely talking about ho-hum efficacy as a single agent, well, that's a class issue. More intriguing is a Genentech ASCO presenter's comment questioning the validity of the target, per Brad Loncar - which you likely saw, and I imagine was the inspiration for your comment "How big is this limb we're on??" Cheers, Tuck

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next